Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Phase 1BexobrutidegPositive

AI Analysis

Nurix Therapeutics announced the first patient enrollment in a Phase 1b/2 combination study evaluating bexobrutideg for chronic lymphocytic leukemia.

Phase

1b/2

Importance:3/10

Sentiment:

0.60

clinical trialpatient enrollmentcombination studyoncology

Related Companies

Read the original article

Published by yahoo_finance on October 7, 2026 5:00 AM